Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
Items 501–600 of 741
Zheng, X., Fang, K., Lin, X., Dai, Z., & Jin, S. (2024) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2024.100838 · Cited by 2
Yang, F., Su, T., Liu, Z., Xia, F., Cheng, Y., Ma, L., & Su, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29711 · Cited by 2
“Despite the good efficacy of these agents in clinical practice, adverse reactions associated with these agents arouse great concern [9,10].”
BackgroundMohammednoor, M., Osman, A. M. E. M., Hamad, S., Ismail, F. I. A., Elamien, M. E. Y. E. M., Gamareldin, E. E. M., & Rahman, M. H. (2025) · Cureus · doi:10.7759/cureus.89201 · Cited by 2
“Current guidelines recommend periodic BMD assessments for COPD patients on ICS [30], yet adherence to these recommendations is often suboptimal [31].”
Research Status and Hot Spot Visualization Analysis of Osteoporosis from 2014 to 2025
Huang, Y., Wang, F., Lian, K., Li, L., & Wang, Z. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s541592 · Cited by 2
Li, C., Xu, L.-P., Zheng, T.-T., & Wu, X.-L. (2026) · Medicine · doi:10.1097/md.0000000000047173 · Cited by 2
“[7] The relationship between IBD and BMD has been extensively studied; however, the findings have been contradictory.”
Uddin, M. J., Gholap, A. D., Saeed, S. M., Kumar, D., Choudhary, N., Choonara, Y. E., Sundaram, G., Webster, T. J., & Faiyazuddin, M. (2026) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-026-01640-x · Cited by 2
Management of glucocorticoid-induced osteoporosis in rheumatic diseases
Shrestha, P., Popuri, S. B., Hoffer, C., Qureshi, A., Barzilay, J. I., Dapaah, E. A., & Carbone, L. D. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102151 · Cited by 2
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Radiomics-based quantitative assessment of the mandibular cortical index on panoramic radiographs
Uzun, S., Dinç, K., & Taşsöker, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-66651-6 · Cited by 2
Chen, G., Guan, Y., Ye, X., Chen, G., Du, J., Liu, W., Zhao, C., Yao, N., & Xu, X. (2020) · Medicine · doi:10.1097/md.0000000000020697 · Cited by 2
Qiu, M., Ding, L., Zhang, M., Lin, J.-H., Huang, H., & Li, K. (2020) · Medicine · doi:10.1097/md.0000000000022690 · Cited by 2
“Although alendronate and other oral bisphosphonates are recommended as first-line agents for primary osteoporosis([5]) and GIOP,([6]) it isn’t suggestive that oral alendronate is suitable for any patient with GIOP.”
BackgroundDisease progression associated with low bone mass in axial spondyloarthropathy patients
Liu, D. H., Chen, J., Zhuang, X. J., & Chen, L. C. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00928-3 · Cited by 2
Efficacy and safety of calcium and vitamin D supplementation to prevent osteoporotic fracture
Kim, B. T. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.305 · Cited by 2
Current Advances in Stem Cell-Based Therapies: Adult Stem Cell Applications
Şanlı, N. M., & Timuroğlu, A. (2024) · Biochemistry · doi:10.5772/intechopen.1007380 · Cited by 2
Zhang, C., Huang, X., Qin, B., Zhang, X., Zhou, L., Pu, Z., Xu, Z., Wu, X., Liu, F., Yang, L., et al. (2025) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073354862241205062019 · Cited by 2
Keikha, F., & Veisian, M. (2021) · Journal of Obstetrics Gynecology and Cancer Research · doi:10.30699/jogcr.6.4.174 · Cited by 2
“Treatment of osteoporosis includes pharmacological therapy, which aims to reduce the risk of fracture (3).”
BackgroundArunthanachaikul, T., & Chaiamnuay, S. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101153 · Cited by 2
Jaramillo, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-62539-5.00030-8 · Cited by 2
Khan, T., Sinha, P. S., & Rosen, H. N. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22071 · Cited by 2
Bao, C., Li, P., Wang, W., Wang, Z., Cai, X., & Zhang, Q. (2024) · Advances in Radiation Oncology · doi:10.1016/j.adro.2024.101558 · Cited by 2
“37 Several pitfalls need to be addressed.”
Benjamin, D. G., & Archana, M. (2024) · Internet Journal of Rheumatology and Clinical Immunology · doi:10.15305/ijrci/v12i1/223 · Cited by 3
“Teriparatide is a recombinant parathyroid hormone (PTH) 1-34, administered subcutaneously for up to two years.”
BackgroundOsteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage
Azad, T. D., Wu, R. J., Anderson, K. E., Darden, M., & Jain, A. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07318-8 · Cited by 2
“…American College of Physicians (2017), American Association of Clinical Endocrinologists (2020), and Bone Health and Osteoporosis Foundation (2022)) recommend the use of pharmacological treatment in women with a new diagnosis of osteoporosis or those at high risk of fragility fractures [5–7].”
Wang, H., Xu, Y. H., Li, P., & Wu, L. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1090 · Cited by 2
Dong, H., Guo, M., Yang, Y., Fu, C., Li, X., & Cheng, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-07099-y · Cited by 2
Postmenopausal Osteoporosis Treatment Update
Wong, E. K. C., & Παπαϊωάννου, Α. (2018) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-018-0098-y · Cited by 2
Kataoka, Y., Luo, Y., Chaimani, A., Ōnishi, A., Kimachi, M., Tsujimoto, Y., Murad, M. H., Li, T., Cipriani, A., & Furukawa, T. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023218 · Cited by 2
“11 The US Food and Drug Administration (FDA) has approved 12 classes of drugs for this condition.(12) Several US and international societies and organisations have developed CPGs for the use of these drugs, but the real-world prescription patterns vary widely.”
BackgroundFriedman, J., Farmer, A., & Fister, J. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_25 · Cited by 2
Management of two-level proximal femoral fractures
Vluggen, T. P. M. J., van Vugt, R., Boonen, B., & Keulen, M. H. F. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-240684 · Cited by 2
Compliance Of Calcium+Vitamin D Treatment Among Elderly
Sarı, A. (2018) · Southern Clinics of Istanbul Eurasia · doi:10.14744/scie.2018.68077 · Cited by 2
Cortical Bone Fracture Imaging using Velocity Model Based Multistatic Synthetic Aperture Ultrasound
Li, Y., Xu, K., Jiang, C., Li, Y., Liu, C., Zhang, J., Hu, B., & Ta, D. (2019) · IEEE International Ultrasonics Symposium · doi:10.1109/ultsym.2019.8925690 · Cited by 2
“Osteoporotic fracture is related with bone mass loss and bone tissue deterioration [1].”
BackgroundBisphosphonate drug holidays: One size does not fit all
DiGiulio, M., Loveless, T., Heider, G., Fagan, K., & Porsche, B. (2020) · The Nurse Practitioner · doi:10.1097/01.npr.0000605524.34681.e7 · Cited by 2
Τhe effect of the first intervention in patients with low bone density
Dedes, V., Tsoni, N., Kafopoulos, D., Tzirogiannis, K. N., Dede, F. M., & Panoutsopoulos, G. I. (2020) · International Journal of Physical Education Sports and Health · doi:10.22271/kheljournal.2020.v7.i4e.1806 · Cited by 3
Deshpande, N. S., & Johnson, K. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-34814-4_15 · Cited by 2
Pastukhova, Y., Luzza, F., Shevel, S., Savchuk, О., Остапченко, Л. І., Falalyeyeva, T. M., Molochek, N., Кuryk, О. G., Korotkyi, O., & Kobyliak, N. M. (2022) · Reviews on Recent Clinical Trials · doi:10.2174/1574887117666220321152855 · Cited by 2
Hassan, D. R. H. R. (2023) · مجلة دراسات وبحوث التربية النوعية · doi:10.21608/jsezu.2023.291522 · Cited by 2
Pathological fractures and the perils of purchasing steroids online
Thor, D. C., & Rome, V. (2024) · Radiology Case Reports · doi:10.1016/j.radcr.2024.09.025 · Cited by 2
“This synergistic mechanism results in an increase in bone resorption and an overall reduction of bone mineral density, thereby generating the opportunity for secondary osteoporosis and subsequent pathological fractures [ 4 ].”
BackgroundMaintaining Bone Health During Hormonal Therapy for Prostate Cancer
Farooki, A., & Scher, H. I. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1800 · Cited by 2
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Miller, P. D. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0486 · Cited by 2
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Frank, E. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0489 · Cited by 2
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
CAREY, J. J., Lewiecki, E. M., Blank, R. D., Shuhart, C., & Buehring, B. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0487 · Cited by 2
Siminoski, K. G., O’Keeffe, M., Akincioğlu, Ç., Ganguli, S., Lévesque, J., Raaphorst, P., Tarulli, G., Thurston, W., & Lyons, D. (2020) · Canadian Association of Radiologists Journal · doi:10.1177/0846537120907655 · Cited by 1
Acute Anterior Uveitis Following Intravenous Zoledronate for Osteoporosis
Rubin, L. A., & Rosenthal, D. S. (2023) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2023.0441 · Cited by 1
A mathematical model for evaluating drug efficacy in multiple myeloma
Yang, Q., Wang, R., Qiao, Y., Zhen, C., & Ji, B. (2025) · Innovation and Emerging Technologies · doi:10.1142/s2737599425500161 · Cited by 1
Halloran, S., Corcoran, K. L., & Lisi, A. J. (2020) · Journal of Contemporary Chiropractic · doi:10.67681/001c.78082 · Cited by 1
Research Article Aclasta effectively treats osteoporosis in patients with femoral head fractures
Toàn, V. T., & Anh, B. V. (2021) · Genetics and Molecular Research · doi:10.4238/gmr18744 · Cited by 1
Yuan, K., Wang, L., Wei, Q., Cheng, X., Chen, Z., Tang, S., Deng, H., & Zhou, W. (2024) · Journal of Imaging Science and Technology · doi:10.2352/j.imagingsci.technol.2024.68.6.060502 · Cited by 1
Iba, K., Hanaka, M., Emori, M., Takashima, K., Teramoto, A., & Takada, J. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j124 · Cited by 1
Ma, Y., Ge, Y., Guo, Z., Su, Y., Wang, C., Wang, Q., Wang, L., Cheng, X., Yang, M., & Yan, D. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-08368-7 · Cited by 1
“…immobility and detrimental effects [9], which impose a considerable economic burden; moreover, according to the osteoporosis guidelines [10, 11], all postmenopausal females with low-energy hip fractures should receive a second hip fracture prevention treatment, and clarifying whether…”
Akab, S. M., Abozeid, H. E., Elazab, S. A., Elazab, S. A. F., ElBazzar, N., Youness, E. R., Shahba, M. A., Orban, H. A., Abdallah, H. R., & Zaki, M. E. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04099-y · Cited by 1
Jiang, J., Zhao, B., Ma, Y., Zeng, Y., Zeng, Y., Fang, J., Kang, W., & Chen, T. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157116 · Cited by 1
Tang, W., Sun, H., You, X., Sun, X. N., Liu, T., Yang, X., & Lin, F. (2025) · European Spine Journal · doi:10.1007/s00586-025-09369-9 · Cited by 1
“…balanced sensitivity (0.900) and specificity (0.995) profile and a higher F1-score, making it preferable for peri-operative use where (OR = 0.335, 95% CI 0.227–0.495), corroborating randomised data that such agents lower incident vertebral fractures by 50–70% in primary osteoporosis [ 25, 26 ].”
InfluentialZhang, H., Zhou, X., & Chen, C. (2025) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2025.103861 · Cited by 1
Cao, B., Dai, X., & Xiao, L. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04608-8 · Cited by 1
“Therefore, osteoclasts are a promising target for the prevention of osteoporosis (Qaseem et al. 2017).”
The orally available SIK2/SIK3 inhibitor SK-124 increases bone mass in hypogonadal male mice
Choi, R. B., Yoon, S.-H., Kotsalidis, P. E., Houghton, C., George, M. A., Brooks, D. J., Zhao, Y., Bouxsein, M., & Wein, M. N. (2026) · JBMR Plus · doi:10.1093/jbmrpl/ziag032 · Cited by 1
Opportunistic Screening Based on Computed Tomography in Musculoskeletal Radiology: How and Why
Dogra, S., Bussey, O., Dane, B. R., Bredella, M. A., & Gyftopoulos, S. (2026) · Seminars in Musculoskeletal Radiology · doi:10.1055/a-2811-6756 · Cited by 1
Chi, M.-C., Shih, K.-S., & Chen, I.-H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135033 · Cited by 1
“The Genant semiquantitative method is widely used to grade OVFs based on height reduction: grade 1 (20–25% reduction), grade 2 (25–40% reduction), and grade 3 (>40% reduction) [23].”
Longitudinal osteoporosis therapy: treat-to-target and sequential strategies—a narrative review
Tskhakaia, I., & Danila, M. I. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261466911 · Cited by 1
Qin, Z., Liao, J., Peng, X., Teng, Y., Wan, B., & Zong, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1950298 · Cited by 1
Kalayjian, R. C., & McComsey, G. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz962 · Cited by 1
Gestagenes in the treatment of endometriosis: efficiency, safety, bioequivalence, transferability
Hryhorenko, A. M. (2021) · Reproductive Endocrinology · doi:10.18370/2309-4117.2021.61.72-75 · Cited by 1
Analysis of Pelvic Bone of Ovariectomized Rats using Infrared and Raman Spectroscopies
Fitriyawardhani, N., Juwono, A. L., & Mulyaningsih, N. N. (2022) · Makara Journal of Science · doi:10.7454/mss.v26i1.1284 · Cited by 1
“When the crystal size decreases, bone density also decreases because the crystal size affects bone density [23].”
BackgroundEpidemiology of Hand and Wrist Injuries in Outdoor Recreational Activities
Weis, J. L., & Matullo, K. S. (2023) · JBJS Journal of Orthopaedics for Physician Assistants · doi:10.2106/jbjs.jopa.22.00017 · Cited by 1
Vitamin D in Children and Adolescents: Are the Needs More Than Skin Deep?
Lazar, K., & Bolander, S. (2018) · JBJS Journal of Orthopaedics for Physician Assistants · doi:10.2106/jbjs.jopa.17.00037 · Cited by 1
Crandall, C. J. (2019) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2019.04.011 · Cited by 1
Safety Considerations for Osteoporosis Therapies
Tile, L., & Cheung, A. M. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_24 · Cited by 1
Osteoporosis and arthropathy in functioning pituitary tumors
Claessen, K. M. J. A., Appelman‐Dijkstra, N. M., & Biermasz, N. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00019-6 · Cited by 1
A Distinction Without a Difference—Does It Matter Whether Fractures Are Nontraumatic or Traumatic?
Schafer, A. L., & Shoback, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2599 · Cited by 1
Tobe, T., Kubo, M., Toda, T., Morita, M., Mika, W., Yamada, S., Suzuki, A., & Hayashi, T. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00017 · Cited by 1
Recommandations sur le dépistage pour la prévention primaire des fractures de fragilisation
Thériault, G., Limburg, H., Klarenbach, S. W., Reynolds, D. L., Riva, J. J., Thombs, B. D., Tessier, L. A., Grad, R. M., Wilson, B. J., & préventifs, P. L. G. D. C. S. L. S. D. S. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221219-f · Cited by 1
A INFLUÊNCIA DO USO DE COSMÉTICOS NO BEM-ESTAR DURANTE A PANDEMIA
Vaz, J. M. D. L., & Lubi, N. C. (2023) · doi:10.22533/at.ed.62423181018 · Cited by 1
AVANÇOS E DESAFIOS DA CIRURGIA ROBÓTICA EM UROLOGIA: UMA REVISÃO DA LITERATURA
de Paiva, Á. T., da Cunha, A. C. B. G., Silva, M. A. D. S., de Oliveira, G. Q., dos Santos, V. O., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Ambrosio, R. D. (2023) · doi:10.22533/at.ed.62423181017 · Cited by 1
Metabolic Diseases and Healthy Aging: Prevention and Public Health Policy Based on Risk Factors
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5639-9 · Cited by 1
Wu, M., Lü, B., Wang, Y., Zhang, A., Zhou, X. H., Zeng, X., Zhu, Y., Chen, S. M., & Lin, R. (2025) · Medicine · doi:10.1097/md.0000000000042652 · Cited by 1
“[2] Consequently, managing bone health effectively remains a critical global concern.”
Clinical Practice Guidelines for Osteoporosis: Translating Data to Patients?
ORWOLL, E. S. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0957 · Cited by 1
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Lamy, O., Aubry‐Rozier, B., & Rodríguez, E. G. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0485 · Cited by 1
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Ott, S. M. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0483 · Cited by 1
Bone Turnover Markers in Osteoporosis—Reply
Bauer, D. C. (2019) · JAMA · doi:10.1001/jama.2019.17671 · Cited by 1
Editorial: Secondary Fracture Prevention—What’s Your System?
Leopold, S. S. (2020) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000001276 · Cited by 1
Surgical treatment for metastatic tumors of the spine.
Kawai, A., Harada, Y., Senda, M., Sugihara, S., Inoue, H., & Nakahara, S. (1996) · PubMed · doi:10.18926/amo/30517 · Cited by 1
Chapter 45: Self-Care Components of Selected Chronic Disorders
Ulbrich, T. R., & Krinsky, D. L. (2015) · The American Pharmacists Association eBooks · doi:10.21019/9781582122250.ch45
Medical management of bone loss from a spinal surgeon’s perspective
Truumees, E. (2017) · Seminars in Spine Surgery · doi:10.1053/j.semss.2017.09.012
Gandhi, V., Nurutdinova, D., Kojic, E. M., & Aberg, J. A. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix932
La prêle des champs : une plante médicinale d'avenir
Laiba, M. B., Douki, W., & Chemli, R. (2018) · Phytothérapie · doi:10.3166/phyto-2018-0025
Updated ACP guideline released on management of osteoporosis
Tanzi, M. G. (2017) · Pharmacy Today · doi:10.1016/j.ptdy.2017.06.026
Longo, D. L. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.58.2018.tde-30082017-081033
Tümer, N. (2018) · Research Repository (Delft University of Technology) · doi:10.4233/uuid:d9b3f849-087e-46a9-96d2-f15d1b573a50
“Based on estimations, 200 million individuals worldwide and 54 million men and women in the United States [6] suffer from the disease.”
BackgroundLeopold, S. S. (2019) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000655
In older postmenopausal women with osteopenia, zoledronate reduced fragility fractures at 6 years
Ensrud, K. E., & Crandall, C. J. (2019) · Annals of Internal Medicine · doi:10.7326/acpj201904160-042
The Effects of Zoledronate and Raloxifene Combination Therapy on Diseased Mouse Bone
Powell, K. M. (2019) · Purdue e-Pubs (Purdue University System) · doi:10.25394/pgs.8023757
Bone Health in Women with Chronic Kidney Disease
Sourial, M. Y., & Coco, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-25324-0_18
Adverse Effects of Androgen Deprivation in Elderly Men with Prostate Cancer
Zarzour, A., Shevach, J. W., & Morgans, A. K. (2019) · Current Geriatrics Reports · doi:10.1007/s13670-019-00303-8
Veazie, S., Gilbert, J., Winchell, K. A., Paynter, R. A., & Guise, J. (2019)
Saverot, S.-E. (2020) · VTechWorks (Virginia Tech)
A Combined Approach to the Treatment of Adults with Osteogenesis Imperfecta
Shapiro, J. R. (2018) · Orthopedics and Sports Medicine Open Access Journal · doi:10.32474/osmoaj.2018.01.000103
Physicians’ Attitudes on Management of Osteopenia in South Korea
Ha, J. H., Kim, H. S., Won, S. J., Lee, Y., & Koo, K. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.3.201
“The questionnaire was made referring to the 2017 American College of Physicians clinical practice guideline on the treatment of low bone density or osteoporosis to prevent fractures.[10] The questionnaire was composed of 6 items: (1) do you think anti-osteoporosis medications are necessary in osteopenia patients?; (2)…”
BackgroundMethodThe Importance of Careful Patient Selection in the Use of Follow-up Bone Mineral Density Testing
Bauer, D. C. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4818
Falls and Fall-Risk-Increasing Drugs (FRIDs)
Springer, S. P., & Carr, M. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.frids_overview
Uso de bifosfonatos en pacientes con osteopenia
Sguiglia, S. (2019) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v22i2.4239
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.